Detectable safety gestalt of rheumatoid arthritis treatments from pivotal clinical drug trials.

d to address by using the MedDRA classification system; (iii) data are not powered to allow statistical comparison of rare AEs, resulting in a purely descriptive comparison of SAEs and AESIs in our study; (iv) the heterogeneity of trial populations and changes in recruiting patterns over time, with a strong trend towards more difficult-to-treat patients and globalizations of recruitment (a substantial number of patients is nowadays being recruited in low and middle income countries, which potentially introduces safety event differences between trials) [ 28 ]; (v) inconsistent reporting of background glucoco

also in 5,725 other papers